Full-Time

Clinical Pharmacist

Ambulatory Care, COPD Population Health Program

Updated on 9/4/2026

Akido

Akido

51-200 employees

AI-powered healthcare platform for scalable care

Compensation Overview

$125k - $135k/yr

Rhode Island, USA

Hybrid

Travel between facilities, provider offices, and practice sites is required.

Bachelor's, PharmD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Word/Pages/Docs
Electronic Health Records (EHR)
Excel/Numbers/Sheets
Microsoft Outlook

Get referred to Akido

See people who can refer or advise you

Requirements
  • Prior experience practicing under a Collaborative Practice Agreement.
  • Current unrestricted pharmacist licensure in accordance with the Rhode Island Board of Registration in Pharmacy.
  • Advanced training and experience relevant to chronic disease management through Board of Pharmaceutical Specialties certification, an ASHP-accredited residency in the area of practice, or a qualifying PharmD or Bachelor of Science in Pharmacy degree with the required professional experience.
  • If the ASHP-accredited residency is not in the area of practice, completion of a continuing education certificate program is required.
  • Practice pharmacy in accordance with applicable laws, rules, and regulations of the Rhode Island Board of Registration in Pharmacy, Department of Public Health, U.S. Food and Drug Administration, and Drug Enforcement Administration, as well as departmental policies and procedures.
  • Work independently at the top of the pharmacist license and make clinical decisions without physician sign-off at every step.
Responsibilities
  • Serve as the medication expert on the interdisciplinary care team.
  • Reconcile and assess medication regimens for adherence, safety, effectiveness, and therapy optimization.
  • Provide evidence-based, patient-centered medication therapy recommendations with providers and care team members.
  • Deliver chronic disease state management services focused on COPD guideline-directed therapy, inhaler technique education, adherence monitoring, and medication access barriers.
  • Identify and engage high-risk COPD patients through population health and care management platforms, including patients with recent emergency department visits, hospital admissions, or readmissions.
  • Conduct transitions-of-care medication evaluations after acute care encounters and coordinate follow-up care.
  • Educate patients on medications, disease states, self-management strategies, and early COPD exacerbation symptoms.
  • Practice within established collaborative practice agreements.
  • Collaborate with providers, patients, payers, and care management teams to provide high-quality, cost-effective care.
  • Participate in developing, implementing, and evaluating quality improvement initiatives and population health programs.
  • Contribute to contractual and organizational quality goals, including comprehensive medication reviews, medication adherence outreach, transitions-of-care initiatives, and closing gaps in care.
  • Document patient encounters and interventions in the electronic health record and other required platforms.
  • Collect, track, and report program outcomes and quality metrics, including utilization, engagement, and clinical outcomes.
  • Develop and deliver presentations on quality metrics, clinical initiatives, and disease-state management topics.
  • Participate in developing new pharmacy services, workflows, and best practices for ambulatory and population health initiatives.
  • Provide coverage and support for additional ambulatory clinical pharmacy services and team initiatives based on departmental needs.
  • Travel between facilities, provider offices, and practice sites.
Desired Qualifications
  • Ambulatory care, population health, or chronic disease management experience.
  • Experience managing respiratory disease states including COPD and asthma, including inhaler technique education.
  • Completion of an ASHP-accredited residency, particularly ambulatory care PGY-1 or PGY-2.
  • Experience working as part of interdisciplinary care teams.
  • Experience supporting transitions of care after hospital discharge or emergency department visits.
  • Experience utilizing electronic health records, population health platforms, and reporting tools.
  • Proficiency with Microsoft Office applications including Word, Excel, Outlook, and web-based systems.

Akido Labs uses artificial intelligence to improve access to high-quality, personalized medical care by connecting providers with an extensive medical network and offering scalable AI-powered tools. Its platform works by integrating AI with the healthcare network to help primary care physicians and specialists expand patient capacity, improve outcomes, and tailor care. It also identifies household-level outbreaks and targets treatments and vaccines where they are most needed, helping to prevent future pandemics. The company differentiates itself through a strong emphasis on empathy, equity, and global access, aiming to bridge advanced medical technology with accessible care and partnering with healthcare providers to scale solutions. Akido Labs’ goal is to make excellent healthcare a basic human right by enabling faster access to care, better outcomes, and proactive public health interventions on a global scale.

Company Size

51-200

Company Stage

Series B

Total Funding

$66.3M

Headquarters

West Hollywood, California

Founded

2015

Get referred to Akido

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Akido said July 30, 2026 revenue grew 300% from 2024 to 2025.
  • The January 28, 2026 Bay Area program put ScopeAI into urgent street-medicine workflows.
  • Oak HC/FT's $60 million Series B funds 2025-2026 expansion and new market entry.

What critics are saying

  • Guardian criticism on January 25, 2026 targets AI diagnosis for low-income patients.
  • CalMatters on January 27, 2026 flagged privacy, bias, and reliability risks in homeless care.
  • If ScopeAI causes a serious adverse event, Medicaid scrutiny can freeze expansion quickly.

What makes Akido unique

  • ScopeAI runs visits across 100 clinics and 1 million covered lives in 2026.
  • Akido combines owned provider network, virtual care, and street medicine into one system.
  • Clinical leadership includes Matt Rothstein, Cambron Carter, and an AI Clinical Advisory Council.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Sick Leave

Paid Vacation

401(k) Retirement Plan

Hybrid Work Options

Remote Work Options

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

1%

2 year growth

-2%
PR Newswire
Jul 30th, 2026
Akido builds first AI-native US health system serving 1M patients across California, New York, and Rhode Island

Akido has announced it is building the first AI-native health system in the US, deploying its ScopeAI technology across 100 clinics and serving 1 million patients in California, New York City, and Rhode Island. The platform organises clinical information in real time, allowing physicians to focus on patient care rather than administration. The company's revenue grew by 300% between 2024 and 2025. ScopeAI has been tested against 203,000 clinical encounters and delivers a Net Promoter Score of 96. Akido is dropping "Labs" from its name and launching Akido Medical as its clinical brand. The company has appointed Matt Rothstein as vice president of engineering and Cambron Carter as principal AI architect. It has also established an AI Clinical Advisory Council to oversee its systems.

Associated Press
Jan 28th, 2026
Bay Area launches first AI-powered safety net programme for unhoused communities

Future Communities Institute has launched the Bay Area's first AI-powered safety net programme in partnership with Five Keys, ReImagine Freedom and Akido Labs. The initiative will use Akido's AI-enabled care model to expand street medicine teams and deliver personalised care to vulnerable populations. The programme addresses growing homelessness in the Bay Area, which has increased 6% year-over-year, with approximately two-thirds of unhoused residents living on the streets. It deploys Akido's ScopeAI system, which guides community health workers through comprehensive patient visits and can initiate medically assisted treatment for substance use disorders within four hours of initial contact. ScopeAI has been trained on over 10 million patient cases and currently supports visits across multiple medical specialties, serving 500,000 patients through Akido's network of 240 clinicians.

PR Newswire
Jan 22nd, 2026
Akido Labs appoints Matt Siegler as chief network officer with 500K+ patients across 3 US states

Akido Labs has appointed Matt Siegler as Chief Network Officer to lead growth and operations across its AI-powered care network serving over 500,000 patients in California, Rhode Island and New York. Siegler previously served as Chief Growth and Strategy Officer at NYC Health & Hospitals, where he drove $6 billion in revenue growth. The company also added Jack Greco, co-founder of $3 billion ACV Auctions, to its board of directors. Cath Anderson joined as Chief Communications Officer, whilst Jim McGee moved into the role of Chief Transformation Officer. The appointments come as Akido reports 300% year-over-year revenue growth into the mid-nine figures. The AI-native healthcare provider operates across 26 specialties and plans rapid expansion in 2026, scaling its risk-bearing care models and ScopeAI clinical platform.

PRWeek
Sep 8th, 2025
Akido Labs hires Catherine Anderson as first chief communications officer

LOS ANGELES: Healthcare technology company Akido Labs has hired Catherine Anderson as chief communications officer, effective Monday.

Wow Partners, Inc.
May 25th, 2025
Akido Labs Raises $60M Series B Funding

Akido Labs, an AI healthcare company, has secured a $60 million Series B funding round led by Oak HC/FT, with participation from Greco, SNR, Y Combinator, Future Communities Capital, and Google's Jeff Dean. The funds will be used to expand the AI system 'ScopeAI', which enhances clinical capabilities and improves healthcare accessibility. ScopeAI allows medical staff to manage more patients without compromising quality, addressing the gap in the U.S. healthcare system's capacity.